Vascular Biogenics' Ovarian Cancer Gene Therapy Study To Continue, Recommends An Independent Committee

Vascular Biogenics Ltd (NASDAQ: VBLT) announces results from the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 study of VB-111 in recurrent ovarian cancer.
According to the results, the committee found no safety issues with the trial and recommended its continuation.
The following DSMC review is scheduled for the third quarter of 2021, followed by completion of enrollment at the end of 2021 or in early 2022
In March last year, interim analysis in the OVAL study demonstrated an overall response rate of 53%. The response rate in the treatment arm (VB-111 in addition to weekly paclitaxel) was at least 10% higher than in the control arm. According to the Company update in November, a high response rate of greater than 50% in the total evaluable patient population was maintained with approximately 200 patients enrolled.
VB-111 (ofranergene obadenovec) is an investigational targeted anti-cancer gene-therapy that uses a dual mechanism to target solid tumors. Its mechanism combines the blockade of tumor vasculature with an anti-tumor immune response. VB-111 is administered as an IV infusion once every 6-8 weeks.
Price Action: VBLT is up 5.29% at $2.42 in market trading hours on the last check Monday.